Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > cancer supportive care drugs market
Get a free sample of Cancer Supportive Care Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Cancer Supportive Care Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Major industry players operating in the cancer supportive care drugs market include :
Global market for cancer supportive care drugs was worth USD 14.4 billion in 2022 and is estimated to expand at 1.9% CAGR from 2023-2032 attributed to the growing progress in cancer treatments, such aschemotherapy, radiation therapy, targeted therapy, and immunotherapy.
The G-CSFs (granulocyte-colony stimulating factors) segment accounted for 22.8% share in the cancer-supportive care drugs market owing to its extensive usage to avoid neutropenia.
Some of the top companies in the industry are Amgen, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Heron Therapeutics, Inc., Novartis AG, GSK plc, F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Teva Pharmaceuticals Industries Ltd., and Fagron Group.
Asia Pacific industry is set to witness 2.3% CAGR from 2023-2032 and reach USD 6.1 billion by 2032 driven by the rising incidence of cancer due to population growth, aging, changing lifestyles, and environmental factors.